Connected Medical Devices: Smarter Care Starts Here

Why It Matters

By streamlining data collection and improving patient compliance, CMD accelerate trial timelines and reduce costs, reshaping the pharmaceutical development landscape.

Key Takeaways

• CMD enable continuous patient data capture, replacing intermittent clinic visits
• Integrated device management improves trial retention and compliance rates
• Service lines like Marken automate data flow, reducing gaps in real‑world evidence
• Calibration and interoperability are critical for reliable primary endpoint measurements
• Decentralized trials using CMD accelerate drug development timelines

Pulse Analysis

The surge in digital health has turned connected medical devices into a strategic asset for pharmaceutical sponsors. Wearables, biosensors, and remote monitoring tools generate high‑frequency physiological data that traditional site visits cannot match. This influx of real‑world evidence not only enriches safety and efficacy assessments but also fuels a burgeoning market projected to exceed $70 billion by 2028, as sponsors seek to lower enrollment barriers and capture diverse patient populations.

Operationalizing CMD, however, demands more than just technology procurement. Robust service lines handle device lifecycle tasks—shipping, calibration, patient onboarding, and data integration—ensuring data integrity and regulatory compliance. Firms like Marken illustrate how automated pipelines can eliminate manual data gaps, feeding continuous streams into electronic data capture systems. Interoperability standards and secure cloud platforms further enable seamless aggregation across heterogeneous hardware, turning raw sensor outputs into actionable trial endpoints.

For the industry, the payoff is tangible: higher retention, faster endpoint readouts, and shortened development cycles. Decentralized trials that leverage CMD can cut site costs by up to 30% and accelerate time‑to‑market for life‑saving therapies. As the approach shifts from niche to norm, organizations that embed CMD management into their logistics infrastructure will gain a competitive edge, delivering more inclusive studies while meeting the growing demand for personalized medicine.